Neurones (XPAR:NRO) Accounts Receivable: €235.4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:NRO Neurones XPAR:NRO
100 GF Score
Price €36.00
GF Value €50.33
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Neurones Accounts Receivable?

Neurones XPAR:NRO -3.49% 100 Accounts Receivable is €235.4 Mil as of Jun. 2026. GuruFocus rates XPAR:NRO with a GF Score™ of 100/100 and a GF Value™ of €50.33 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Neurones's accounts receivables for the quarter that ended in Jun. 2026 was €235.4 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Neurones's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 94.47.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Neurones's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was €5.24.


Neurones Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Neurones's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=235.442/454.845*91
=94.47

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Neurones's accounts receivable are only considered to be worth 75% of book value:

Neurones's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(301.875+0.75 * 235.442+0.5 * 0.63-296.683
-0-57.174)/23.842455
=5.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Neurones Accounts Receivable Related Terms


Neurones Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Neurones's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurones Accounts Receivable Chart

Neurones Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 164.64 192.23 206.11 214.11 216.56

Neurones Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 235.12 214.11 235.13 216.56 235.44
XPAR:NRO
100GF Score
Neurones XPAR:NRO
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurones Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of €235.4 Mil mean?
Neurones (XPAR:NRO) has a Accounts Receivable of €235.4 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Neurones and its competitors.
Is Neurones' Accounts Receivable too high?
Neurones' current Accounts Receivable is €235.4 Mil. Overall, Neurones has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurones' Accounts Receivable compare to IBM and ACN?
Neurones' Accounts Receivable of €235.4 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Software company?
A good Accounts Receivable depends on the Software industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Neurones and its competitors. Neurones's current Accounts Receivable is €235.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurones stock overvalued right now?
Based on GuruFocus' analysis, Neurones (XPAR:NRO) is currently considered Modestly Undervalued. The stock's GF Value™ is €50.33, compared to a current price of €36.00 — trading 28.5% below its estimated fair value. The current Accounts Receivable is €235.4 Mil. Neurones' overall GF Score™ is 100/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Neurones (XPAR:NRO), the current Accounts Receivable is €235.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurones (XPAR:NRO) Overvalued in 2026?

Based on GuruFocus' analysis, Neurones stock appears to be undervalued. The current stock price of €36.00 is trading 28.5% below its estimated GF Value™ of €50.33. GuruFocus considers Neurones to be Modestly Undervalued.

Key valuation signals for XPAR:NRO:

  • Accounts Receivable: €235.4 Mil
  • GF Value™: €50.33 vs. price of €36.00 (28.5% below fair value)
  • GF Score™: 100/100 with 3 warning signs

No single metric tells the full story. See the XPAR:NRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neurones Business Description

Other Exchanges 0GX2:UKNE9:Germany
Address 205 Avenue Georges Clemenceau, Immeuble Le Clemenceau 1 Building, Nanterre, FRA, 92024
Neurones is active in Consulting and Digital Services, with activities including Digital Transformation, Overall Offer, Infrastructure Hub, Applications Hub, Consulting Division, Managed Services, and Service Centers. It also conducts IT development, pre-sales activities, management of fixed-price projects, technical assistance, infrastructure operations, and cybersecurity, and provides an internal platform for multi-LLM assistants, including Microsoft Copilot, ChatGPT, Gemini, Claude, and Mistral. Its segments are Infrastructure Services, Application Services, and Consulting. Infrastructure Services generates the majority of revenue and includes Cloud, Infrastructure Management, DevOps, Cybersecurity, User Support, IT Service Management, Information System Governance, and Automation.
100GF Score

Get the complete analysis for XPAR:NRO

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€36.00
Price
€50.33
GF Value